Health inequalities research involving the pharmaceutical industry globally: a scoping review.

IF 2.4 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Current Medical Research and Opinion Pub Date : 2025-02-01 Epub Date: 2025-02-19 DOI:10.1080/03007995.2025.2465618
Maciej Czachorowski, Richard Mandunya, Lynne Corner, Rachel Russell, Lynne Hayward, Joseph Hawkins, Adeline Rosenberg, Natalie Bohm
{"title":"Health inequalities research involving the pharmaceutical industry globally: a scoping review.","authors":"Maciej Czachorowski, Richard Mandunya, Lynne Corner, Rachel Russell, Lynne Hayward, Joseph Hawkins, Adeline Rosenberg, Natalie Bohm","doi":"10.1080/03007995.2025.2465618","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To assess health inequalities research involving the pharmaceutical industry and to highlight key themes and potential research gaps.</p><p><strong>Methods: </strong>Briefly, a literature search of article titles on the Embase and MEDLINE databases was performed to identify relevant peer-reviewed literature published between 2000 and 2023. A review of gray literature sources and pharmaceutical company global websites was performed in parallel. Peer-reviewed literature and gray literature were excluded during pre-screening based on pre-defined eligibility criteria. Peer-reviewed publications that met the eligibility criteria underwent double-blind title and abstract screening to determine relevance to health inequalities research; gray literature was screened by one reviewer. All publications included after title and abstract screening underwent full-text review.</p><p><strong>Results: </strong>The peer-reviewed literature search yielded 1,377 initial results, of which 18 publications were included for data extraction; the gray literature search yielded 10 articles. Peer-reviewed publications involving the pharmaceutical industry increased over the past 5 years. North America was included as the region of research focus or study population in 61.1% (11/18) of the peer-reviewed publications. Health inequalities across race/ethnicity (66.7% [12/18]), sex/gender (44.4% [8/18]) and socioeconomic status (27.8% [5/18]) featured in the identified publications. Across the medicines and vaccines development and launch process, 71.4% (5/7) of the publications focused on increasing clinical trial participant diversity.</p><p><strong>Conclusions: </strong>The pharmaceutical industry has contributed to the discussion on health inequalities, particularly over the past 5 years. However, industry can better take the wider determinants of health into consideration when designing strategies of evidence generation across the medicines development pathway.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"227-237"},"PeriodicalIF":2.4000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Medical Research and Opinion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/03007995.2025.2465618","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To assess health inequalities research involving the pharmaceutical industry and to highlight key themes and potential research gaps.

Methods: Briefly, a literature search of article titles on the Embase and MEDLINE databases was performed to identify relevant peer-reviewed literature published between 2000 and 2023. A review of gray literature sources and pharmaceutical company global websites was performed in parallel. Peer-reviewed literature and gray literature were excluded during pre-screening based on pre-defined eligibility criteria. Peer-reviewed publications that met the eligibility criteria underwent double-blind title and abstract screening to determine relevance to health inequalities research; gray literature was screened by one reviewer. All publications included after title and abstract screening underwent full-text review.

Results: The peer-reviewed literature search yielded 1,377 initial results, of which 18 publications were included for data extraction; the gray literature search yielded 10 articles. Peer-reviewed publications involving the pharmaceutical industry increased over the past 5 years. North America was included as the region of research focus or study population in 61.1% (11/18) of the peer-reviewed publications. Health inequalities across race/ethnicity (66.7% [12/18]), sex/gender (44.4% [8/18]) and socioeconomic status (27.8% [5/18]) featured in the identified publications. Across the medicines and vaccines development and launch process, 71.4% (5/7) of the publications focused on increasing clinical trial participant diversity.

Conclusions: The pharmaceutical industry has contributed to the discussion on health inequalities, particularly over the past 5 years. However, industry can better take the wider determinants of health into consideration when designing strategies of evidence generation across the medicines development pathway.

涉及全球制药业的保健不平等研究:范围审查。
目的:评估涉及制药业的卫生不平等研究,并突出关键主题和潜在的研究差距。方法:简单地检索Embase和MEDLINE数据库的文章标题,找出2000 - 2023年发表的相关同行评审文献。对灰色文献来源和制药公司全球网站的审查同时进行。同行评议文献和灰色文献在基于预先定义的资格标准的预筛选中被排除。对符合资格标准的同行评议出版物进行双盲标题和摘要筛选,以确定与健康不平等研究的相关性;灰色文献由一位审稿人筛选。标题和摘要筛选后纳入的所有出版物进行全文审查。结果:同行评议文献检索共获得1377个初步结果,其中18篇文献被纳入数据提取;灰色文献检索产生了10篇文章。涉及制药业的同行评议出版物在过去5年中有所增加。61.1%(11/18)的同行评议出版物将北美作为研究重点或研究人群。在已确定的出版物中提到了种族/族裔(66.7%[12/18])、性别/性别(44.4%[8/18])和社会经济地位(27.8%[5/18])之间的卫生不平等。在整个药物和疫苗开发和上市过程中,71.4%(5/7)的出版物侧重于增加临床试验参与者的多样性。结论:制药业促进了关于保健不平等问题的讨论,特别是在过去5年中。然而,在设计跨药物开发途径的证据生成战略时,工业界可以更好地考虑到更广泛的健康决定因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current Medical Research and Opinion
Current Medical Research and Opinion 医学-医学:内科
CiteScore
4.40
自引率
4.30%
发文量
247
审稿时长
3-8 weeks
期刊介绍: Current Medical Research and Opinion is a MEDLINE-indexed, peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, Phase II-IV studies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged. Preclinical, Phase I, pharmacoeconomic, outcomes and quality of life studies may also be considered if there is clear clinical relevance
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信